Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-105855
Filing Date
2025-08-08
Accepted
2025-08-08 16:15:47
Documents
67
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ck0001991792-20250630.htm   iXBRL 10-Q 2044484
2 EX-31.1 ck0001991792-ex31_1.htm EX-31.1 16610
3 EX-31.2 ck0001991792-ex31_2.htm EX-31.2 16445
4 EX-32.1 ck0001991792-ex32_1.htm EX-32.1 10778
5 EX-32.2 ck0001991792-ex32_2.htm EX-32.2 10898
  Complete submission text file 0000950170-25-105855.txt   7723868

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001991792-20250630.xsd EX-101.SCH 1118184
70 EXTRACTED XBRL INSTANCE DOCUMENT ck0001991792-20250630_htm.xml XML 1244763
Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41925 | Film No.: 251198614
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)